SpectraCure initiates process for change of listing
The Board of SpectraCure AB ("SpectraCure" or the "Company") has decided to initiate a process for change of listing, from AktieTorget to Nasdaq First North Premier. The company's ambition is to implement the list change to Nasdaq First North Premier during 2018.
A listing on First North Premier is expected to create favorable conditions for improved liquidity in the stock and increased opportunities for institutional parties to invest in SpectraCure. Listing on First North Premier is also judged to be an additional quality mark for SpectraCure regarding the Company's dissemination and operations, which will create good conditions for deepening cooperation with existing ones, and finding New international partners.
– Our performance on AktieTorget has been very positive. AktieTorget has, through a high level of service and professional treatment, supported us in our development and ensured effective trading in our share. It has been an important marketplace for us until now, when we are aiming for First North Premier. We thank AktieTorget for a good cooperation, says Masoud Khayyami, CEO of SpectraCure AB.
This information is information that SpectraCure AB is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the below contact person, for publication on February 15th, 2018.
For further information, please contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 9
SpectraCure in short
SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region